Age-related alterations in meningeal immunity drive impaired CNS lymphatic drainage.

"the data underlying fig 1 b-e ; fig s2 d and e ; and fig s3 b-e are openly available in the gene expression omnibus under accession number gse217314 .; the data underlying fig 1 f-h ; fig s1 a-e ; and fig s2 a-c are openly available in the gene expression omnibus under the accession number gse161290 ."

"Disclosures: R.D. Kamm reported “other” from AIM Biotech and grants from Novartis, Roche, Boehringer-Ingelheim, Amgen, AbbVie, Takeda, Eisai, Merck KGaA, and Visterra outside the submitted work. In addition, R.D. Kamm had a patent for microfluidic platform with royalties paid (AIM Biotech). J. Kipnis reported a patent for US20210311076A1 pending. No other disclosures were reported."

"This work was conducted with funding from National Institutes of Health grants R01AG078667, R37AG034113, R01AT011419 (J. Kipnis), R01 NS121078 (R.D. Kamm), and R01HL142905, R01HL164825 (J.P. Scallan); the Royal Society of New Zealand Te Apārangi Rutherford Discovery Fellowship (J. Rustenhoven); the Cure Alzheimer’s Fund (G. Pavlou and J. Kipnis); and the Ludwig Family Foundation (J. Kipnis). Disclosures: R.D. Kamm reported “other” from AIM Biotech and grants from Novartis, Roche, Boehringer-Ingelheim, Amgen, AbbVie, Takeda, Eisai, Merck KGaA, and Visterra outside the submitted work. In addition, R.D. Kamm had a patent for microfluidic platform with royalties paid (AIM Biotech). J. Kipnis reported a patent for US20210311076A1 pending. No other disclosures were reported."